BACKGROUND: Trastuzumab (Herceptin  , Roche) has significantly improved the prognosis of @entity1 with @entity1722 -positive metastatic @entity0 . Some @entity1 remain in remission for many years. However, there are no prognostic markers associated with long-term survival. This study aimed to analyse treatment patterns of @entity1722 -positive metastatic @entity0 at a single institution and explore prognostic factors for long-term survival after @entity1722 -targeted treatment. @entity1 AND METHODS: This was a retrospective cohort study of all @entity1 with @entity1722 -positive metastatic @entity0 receiving first-line treatment with @entity1722 -targeted therapy between 2004 and 2014 at the University Hospital of Zurich (n = 81). @entity1349 ( @entity1349 ) and other time-to-event endpoints were determined with Kaplan-Meier curves and clinicopathological factors predicting long-term outcome were identified by use of the log-rank test. RESULTS: The median @entity1349 for the cohort was 5.9 years (95% confidence interval [CI] 3.5-8.3). Twenty @entity1 (28.6%) remained in complete remission after 1 year, 11 (15.7%) after 2 years and 4 (5.7%) beyond 5 years. The median progression-free survival was 13.6 months (95% CI 9.0-18.3). The objective response rate (ORR) was 60.5% with 16 (19.8%) complete responses and 33 (40.8%) partial responses. Six (7.4%) @entity1 had brain metastases as first site of relapse and they had a median @entity1349 of 1.9 years (95% CI 1.7-2.2 years). Thirty-four of all 81 @entity1 (42%) had developed brain metastases by the time of @entity204 or last follow-up. Median @entity1349 after diagnosis of brain metastases was 26 months (95% CI 19.9-32.0). Only primary brain metastases were found to be a prognostic marker associated with shorter overall survival. Hormone-receptor status and presence of visceral metastases at primary diagnosis were not associated with prognosis. Only four @entity1 (4.9%) developed some degree of @entity1002 under treatment with trastuzumab. CONCLUSIONS: @entity1722 -targeted treatment has improved the overall survival of @entity1 with @entity1722 -postive metastatic @entity0 with median @entity1349 exceeding 5 years. There are, however, no predictive markers for a long-term survival. Only the absence of primary brain metastases seems to be an indicator of a good prognosis.

Exploring prognostic factors for XXXX -positive metastatic @entity0 : a retrospective cohort study in a major Swiss hospital.

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity1002 :: ('MESH:D018487', 'Disease') :: ['left ventricular dysfunction'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'Overall survival'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity1722 :: ('2064', 'Gene') :: ['HER2']
@entity1722 :: (2064,Gene) :: ['HER2']
